Laura K. Ferris
Expertise in
7
conditions

Dr. Laura K. Ferris

Dermatology | Pediatrics | General Practice
UNC Dermatology & Skin Cancer Center
410 Market St Ste 400A, 
Chapel Hill, NC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Expertise in
7
conditions
UNC Dermatology & Skin Cancer Center
410 Market St Ste 400A, 
Chapel Hill, NC 

Overview

Laura Ferris is a Dermatologist and an Internal Medicine provider practicing medicine in Chapel Hill, North Carolina.

Dr. Ferris is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Psoriasis, Plaque Psoriasis, Melanoma, and Familial Atypical Multiple Mole Melanoma Syndrome.

She is actively involved in clinical research, co-authoring 135 peer reviewed articles and participating in 10 clinical trials. Dr. Ferris is currently accepting new patients.

Specialties

Dermatology
Pediatrics
General Practice

Licenses

Specialist in PA

Hospital Affiliations

Unc Hospitals

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
HealthPartners
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Paramount
  • EPO
  • HMO
  • INDEMNITY
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

UNC Dermatology & Skin Cancer Center
410 Market St Ste 400A, Chapel Hill, NC 27516
Other Locations
Office
3601 5th Ave Ste 5A, Pittsburgh, PA 15213

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Targeting Nociceptors in Hidradenitis Suppurativa
Targeting Nociceptors in Hidradenitis Suppurativa
Enrollment Status: Recruiting
Publish Date: August 07, 2026
Intervention Type: Drug
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: April 16, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 2/Phase 3
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations
Enrollment Status: Completed
Publish Date: November 07, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Multiple-Dose, Randomized, Placebo-Controlled, Study of LY3462817 or LY3509754 in Patients With Psoriasis
A Multiple-Dose, Randomized, Placebo-Controlled, Study of LY3462817 or LY3509754 in Patients With Psoriasis
Enrollment Status: Terminated
Publish Date: March 15, 2022
Intervention Type: Drug
Study Drugs: LY3462817-IV, LY3462817-SV
Study Phase: Phase 1
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
View 8 Less Clinical Trials

135 Total Publications

Deuterated Pentoxifylline Analog in the Treatment of Necrobiosis Lipoidica: A Nonrandomized Clinical Trial.
Deuterated Pentoxifylline Analog in the Treatment of Necrobiosis Lipoidica: A Nonrandomized Clinical Trial.
Journal: JAMA dermatology
Published: April 29, 2026
Similar Doctors
Expertise in
19
conditions
Expertise in
19
conditions
Referral required
Before you request

Duke Pediatric Dermatology Patterson Place

5324 McFarland Rd, 
Durham, NC 
 (9.6 miles away)
919-401-7733
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniela Kroshinsky is a Dermatologist practicing medicine in Durham, North Carolina. Dr. Kroshinsky is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Calciphylaxis, Cellulitis, Calcinosis, and Acute Febrile Neutrophilic Dermatosis. Dr. Kroshinsky is board certified in American Board Of Dermatology, Dermatology. Dr. Kroshinsky is currently accepting new patients.

Expertise in
9
conditions
Dr. Auris O. Huen
Dermatology
Expertise in
9
conditions
Dr. Auris O. Huen
Dermatology
Referral may be required
Before you request

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (24.6 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Auris Huen is a Dermatologist practicing medicine in Cary, North Carolina. Dr. Huen is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Mycosis Fungoides, T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), and Lymphomatoid Papulosis. Dr. Huen is currently accepting new patients.

Expertise in
9
conditions
Expertise in
9
conditions
Referral may be required

Duke Health Integrated Practice Inc

40 Duke Medicine Cir, 
Durham, NC 
 (14.0 miles away)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Priya Kishnani is a Pediatrics provider practicing medicine in Durham, North Carolina. Dr. Kishnani is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Pompe Disease, Glycogen Storage Disease Type 3, Hypophosphatasia (HPP), Glycogen Storage Disease Type 9, and Splenectomy. Dr. Kishnani is currently accepting new patients.

Frequently Asked Questions about Dr. Laura K. Ferris

How do I make an appointment with Dr. Laura K. Ferris?

You can book an appointment with Dr. Laura K. Ferris by calling their office at 984-974-3900. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Laura K. Ferris a top-rated expert for Psoriasis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Laura K. Ferris is classified as an Elite expert for Psoriasis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Laura K. Ferris specialize in?

While Dr. Laura K. Ferris is a Dermatology, they have specific expertise in Psoriasis, Plaque Psoriasis, and Melanoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Laura K. Ferris participate in research or clinical trials?

Yes. Dr. Laura K. Ferris has published 135 articles and abstracts on conditions like Psoriasis. You can view a list of Dr. Laura K. Ferris's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Laura K. Ferris accept my insurance?

Dr. Laura K. Ferris accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 984-974-3900 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ferris's expertise for a condition
ConditionClose
View All 101 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile